SOD1 explained

Superoxide dismutase [Cu-Zn] also known as superoxide dismutase 1 or hSod1 is an enzyme that in humans is encoded by the SOD1 gene, located on chromosome 21. SOD1 is one of three human superoxide dismutases.[1] [2] It is implicated in apoptosis, familial amyotrophic lateral sclerosis and Parkinson's disease.[2] [3]

Structure

SOD1 is a 32 kDa homodimer which forms a beta barrel (β-barrel) and contains an intramolecular disulfide bond and a binuclear Cu/Zn site in each subunit. This Cu/Zn site holds the copper and a zinc ion and is responsible for catalyzing the disproportionation of superoxide to hydrogen peroxide and dioxygen.[4] [5] The maturation process of this protein is complex and not fully understood, involving the selective binding of copper and zinc ions, formation of the intra-subunit disulfide bond between Cys-57 and Cys-146, and dimerization of the two subunits. The copper chaperone for Sod1 (CCS) facilitates copper insertion and disulfide oxidation. Although SOD1 is synthesized in the cytosol and can mature there, the fraction of expressed but still immature SOD1 that is targeted to the mitochondria must be inserted into the intermembrane space. There, it forms the disulfide bond, though not metalation, required for its maturation.[5] The mature protein is highly stable,[6] but unstable when in its metal-free and disulfide-reduced forms.[4] [5] [6] This manifests in vitro, as the loss of metal ions results in increased SOD1 aggregation, and in disease models, where low metalation is observed for insoluble SOD1. Moreover, the surface-exposed reduced cysteines could participate in disulfide crosslinking and, thus, aggregation.[4]

Function

SOD1 binds copper and zinc ions and is one of three superoxide dismutases responsible for destroying free superoxide radicals in the body. The encoded isozyme is a soluble cytoplasmic and mitochondrial intermembrane space protein, acting as a homodimer to convert naturally occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide.[5] Hydrogen peroxide can then be broken down by another enzyme called catalase.

SOD1 has been postulated to localize to the outer mitochondrial membrane (OMM), where superoxide anions would be generated, or the intermembrane space. The exact mechanisms for its localization remains unknown, but its aggregation to the OMM has been attributed to its association with BCL-2. Wildtype SOD1 has demonstrated antiapoptotic properties in neural cultures, while mutant SOD1 has been observed to promote apoptosis in spinal cord mitochondria, but not in liver mitochondria, though it is equally expressed in both. Two models suggest SOD1 inhibits apoptosis by interacting with BCL-2 proteins or the mitochondria itself.[2]

Clinical significance

Role in oxidative stress

Most notably, SOD1 is pivotal in reactive oxygen species (ROS) release during oxidative stress by ischemia-reperfusion injury, specifically in the myocardium as part of a heart attack (also known as ischemic heart disease). Ischemic heart disease, which results from an occlusion of one of the major coronary arteries, is currently still the leading cause of morbidity and mortality in western society.[7] [8] During ischemia reperfusion, ROS release substantially contribute to the cell damage and death via a direct effect on the cell as well as via apoptotic signals. SOD1 is known to have a capacity to limit the detrimental effects of ROS. As such, SOD1 is important for its cardioprotective effects.[9] In addition, SOD1 has been implicated in cardioprotection against ischemia-reperfusion injury, such as during ischemic preconditioning of the heart.[10] Although a large burst of ROS is known to lead to cell damage, a moderate release of ROS from the mitochondria, which occurs during nonlethal short episodes of ischemia, can play a significant triggering role in the signal transduction pathways of ischemic preconditioning leading to reduction of cell damage. It has even observed that during this release of ROS, SOD1 plays an important role hereby regulating apoptotic signaling and cell death.

In one study, deletions in the gene were reported in two familial cases of keratoconus.[11] Mice lacking SOD1 have increased age-related muscle mass loss (sarcopenia), early development of cataracts, macular degeneration, thymic involution, hepatocellular carcinoma, and shortened lifespan.[12] Research suggests that increased SOD1 levels could be a biomarker for chronic heavy metal toxicity in women with long-term dental amalgam fillings.[13]

Amyotrophic lateral sclerosis (Lou Gehrig's disease)

Mutations (over 150 identified to date) in this gene have been linked to familial amyotrophic lateral sclerosis.[14] [15] [16] However, several pieces of evidence also show that wild-type SOD1, under conditions of cellular stress, is implicated in a significant fraction of sporadic ALS cases, which represent 90% of ALS patients.[17] The most frequent mutations are A4V (in the U.S.A.) and H46R (Japan). In Iceland only SOD1-G93S has been found. The most studied ALS mouse model is G93A. Rare transcript variants have been reported for this gene.[18]

Virtually all known ALS-causing SOD1 mutations act in a dominant fashion; a single mutant copy of the SOD1 gene is sufficient to cause the disease. The exact molecular mechanism (or mechanisms) by which SOD1 mutations cause disease are unknown. It appears to be some sort of toxic gain of function,[16] as many disease-associated SOD1 mutants (including G93A and A4V) retain enzymatic activity and Sod1 knockout mice do not develop ALS (although they do exhibit a strong age-dependent distal motor neuropathy).

ALS is a neurodegenerative disease characterized by selective loss of motor neurons causing muscle atrophy. The DNA oxidation product 8-OHdG is a well-established marker of oxidative DNA damage. 8-OHdG accumulates in the mitochondria of spinal motor neurons of persons with ALS.[19] In transgenic ALS mice harboring a mutant SOD1 gene, 8-OHdG also accumulates in mitochondrial DNA of spinal motor neurons.[20] These findings suggest that oxidative damage to mitochondrial DNA of motor neurons due to altered SOD1 may be significant factor in the etiology of ALS.

A4V mutation

A4V (alanine at codon 4 changed to valine) is the most common ALS-causing mutation in the U.S. population, with approximately 50% of SOD1-ALS patients carrying the A4V mutation.[21] [22] [23] Approximately 10 percent of all U.S. familial ALS cases are caused by heterozygous A4V mutations in SOD1. The mutation is rarely if ever found outside the Americas.

It was recently estimated that the A4V mutation occurred 540 generations (~12,000 years) ago. The haplotype surrounding the mutation suggests that the A4V mutation arose in the Asian ancestors of Native Americans, who reached the Americas through the Bering Strait.[24]

The A4V mutant belongs to the WT-like mutants. Patients with A4V mutations exhibit variable age of onset, but uniformly very rapid disease course, with average survival after onset of 1.4 years (versus 3–5 years with other dominant SOD1 mutations, and in some cases such as H46R, considerably longer). This survival is considerably shorter than non-mutant SOD1 linked ALS.

H46R mutation

H46R (histidine at codon 46 changed to arginine) is the most common ALS-causing mutation in the Japanese population, with about 40% of Japanese SOD1-ALS patients carrying this mutation. H46R causes a profound loss of copper binding in the active site of SOD1, and as such, H46R is enzymatically inactive. The disease course of this mutation is extremely long, with the typical time from onset to death being over 15 years.[25] Mouse models with this mutation do not exhibit the classical mitochondrial vacuolation pathology seen in G93A and G37R ALS mice and unlike G93A mice, deficiency of the major mitochondrial antioxidant enzyme, SOD2, has no effect on their disease course.[25]

G93A mutation

G93A (glycine 93 changed to alanine) is a comparatively rare mutation, but has been studied very intensely as it was the first mutation to be modeled in mice. G93A is a pseudo-WT mutation that leaves the enzyme activity intact.[23] Because of the ready availability of the G93A mouse from Jackson Laboratory, many studies of potential drug targets and toxicity mechanisms have been carried out in this model. At least one private research institute (ALS Therapy Development Institute) is conducting large-scale drug screens exclusively in this mouse model. Whether findings are specific for G93A or applicable to all ALS-causing SOD1 mutations is at present unknown. It has been argued that certain pathological features of the G93A mouse are due to overexpression artifacts, specifically those relating to mitochondrial vacuolation (the G93A mouse commonly used from Jackson Lab has over 20 copies of the human SOD1 gene).[26] At least one study has found that certain features of pathology are idiosyncratic to G93A and not extrapolatable to all ALS-causing mutations.[25] Further studies have shown that the pathogenesis of the G93A and H46R models are clearly distinct; some drugs and genetic interventions that are highly beneficial/detrimental in one model have either the opposite or no effect in the other.[27] [28] [29]

Down syndrome

Down syndrome (DS) is usually caused by a triplication of chromosome 21. Oxidative stress is thought to be an important underlying factor in DS-related pathologies. The oxidative stress appears to be due to the triplication and increased expression of the SOD1 gene located in chromosome 21. Increased expression of SOD1 likely causes increased production of hydrogen peroxide leading to increased cellular injury.

The levels of 8-OHdG in the DNA of persons with DS, measured in saliva, were found to be significantly higher than in control groups.[30] 8-OHdG levels were also increased in the leukocytes of persons with DS compared to controls.[31] These findings suggest that oxidative DNA damage may lead to some of the clinical features of DS.

Interactions

SOD1 has been shown to interact with CCS[32] and Bcl-2.[33] [34] [35] [36]

Further reading

112-115. sod 1

Notes and References

  1. Milani P, Gagliardi S, Cova E, Cereda C . SOD1 Transcriptional and Posttranscriptional Regulation and Its Potential Implications in ALS . Neurology Research International . 2011 . 458427 . 2011 . 21603028 . 3096450 . 10.1155/2011/458427 . free .
  2. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX . 6 . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis . Nature . 362 . 6415 . 59–62 . March 1993 . 8446170 . 10.1038/362059a0 . 265436 . 1993Natur.362...59R .
  3. Trist BG, Hilton JB, Hare DJ, Crouch PJ, Double KL . Superoxide Dismutase 1 in Health and Disease: How a Frontline Antioxidant Becomes Neurotoxic . Angewandte Chemie . 60 . 17 . 9215–9246 . April 2021 . 32144830 . 8247289 . 10.1002/anie.202000451 .
  4. Estácio SG, Leal SS, Cristóvão JS, Faísca PF, Gomes CM . Calcium binding to gatekeeper residues flanking aggregation-prone segments underlies non-fibrillar amyloid traits in superoxide dismutase 1 (SOD1) . Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics . 1854 . 2 . 118–126 . February 2015 . 25463043 . 10.1016/j.bbapap.2014.11.005 .
  5. Sea K, Sohn SH, Durazo A, Sheng Y, Shaw BF, Cao X, Taylor AB, Whitson LJ, Holloway SP, Hart PJ, Cabelli DE, Gralla EB, Valentine JS . 6 . Insights into the role of the unusual disulfide bond in copper-zinc superoxide dismutase . The Journal of Biological Chemistry . 290 . 4 . 2405–2418 . January 2015 . 25433341 . 4303690 . 10.1074/jbc.M114.588798 . free .
  6. Khare SD, Caplow M, Dokholyan NV . The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis . Proceedings of the National Academy of Sciences of the United States of America . 101 . 42 . 15094–15099 . October 2004 . 15475574 . 524068 . 10.1073/pnas.0406650101 . free . 2004PNAS..10115094K .
  7. Murray CJ, Lopez AD . Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study . Lancet . 349 . 9064 . 1498–1504 . May 1997 . 9167458 . 10.1016/S0140-6736(96)07492-2 . 10556268 .
  8. Braunwald E, Kloner RA . Myocardial reperfusion: a double-edged sword? . The Journal of Clinical Investigation . 76 . 5 . 1713–1719 . November 1985 . 4056048 . 424191 . 10.1172/JCI112160 .
  9. Maslov LN, Naryzhnaia NV, Podoksenov I, Prokudina ES, Gorbunov AS, Zhang I, Peĭ Z . [Reactive oxygen species are triggers and mediators of an increase in cardiac tolerance to impact of ischemia-reperfusion] . Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova . 101 . 1 . 3–24 . January 2015 . 25868322 .
  10. Liem DA, Honda HM, Zhang J, Woo D, Ping P . Past and present course of cardioprotection against ischemia-reperfusion injury . Journal of Applied Physiology . 103 . 6 . 2129–2136 . December 2007 . 17673563 . 10.1152/japplphysiol.00383.2007 . 24815784 .
  11. Udar N, Atilano SR, Brown DJ, Holguin B, Small K, Nesburn AB, Kenney MC . SOD1: a candidate gene for keratoconus . Investigative Ophthalmology & Visual Science . 47 . 8 . 3345–3351 . August 2006 . 16877401 . 10.1167/iovs.05-1500 . free .
  12. Muller FL, Lustgarten MS, Jang Y, Richardson A, Van Remmen H . Trends in oxidative aging theories . Free Radical Biology & Medicine . 43 . 4 . 477–503 . August 2007 . 17640558 . 10.1016/j.freeradbiomed.2007.03.034 .
  13. Cabaña-Muñoz ME, Parmigiani-Izquierdo JM, Bravo-González LA, Kyung HM, Merino JJ . Increased Zn/Glutathione Levels and Higher Superoxide Dismutase-1 Activity as Biomarkers of Oxidative Stress in Women with Long-Term Dental Amalgam Fillings: Correlation between Mercury/Aluminium Levels (in Hair) and Antioxidant Systems in Plasma . PLOS ONE . 10 . 6 . e0126339 . June 2015 . 26076368 . 4468144 . 10.1371/journal.pone.0126339 . free . 2015PLoSO..1026339C .
  14. Conwit RA . Preventing familial ALS: a clinical trial may be feasible but is an efficacy trial warranted? . Journal of the Neurological Sciences . 251 . 1–2 . 1–2 . December 2006 . 17070848 . 10.1016/j.jns.2006.07.009 . 33105812 .
  15. Al-Chalabi A, Leigh PN . Recent advances in amyotrophic lateral sclerosis . Current Opinion in Neurology . 13 . 4 . 397–405 . August 2000 . 10970056 . 10.1097/00019052-200008000-00006 . 21577500 .
  16. Book: Redler RL, Dokholyan NV . The complex molecular biology of amyotrophic lateral sclerosis (ALS) . 107 . 215–62 . 2012-01-01 . 22482452 . 3605887 . 10.1016/B978-0-12-385883-2.00002-3 . Progress in Molecular Biology and Translational Science . 9780123858832 . Molecular Biology of Neurodegenerative Diseases .
  17. Gagliardi S, Cova E, Davin A, Guareschi S, Abel K, Alvisi E, Laforenza U, Ghidoni R, Cashman JR, Ceroni M, Cereda C . 6 . SOD1 mRNA expression in sporadic amyotrophic lateral sclerosis . Neurobiology of Disease . 39 . 2 . 198–203 . August 2010 . 20399857 . 10.1016/j.nbd.2010.04.008 . 207065284 .
  18. Web site: Entrez Gene: SOD1 superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)).
  19. Kikuchi H, Furuta A, Nishioka K, Suzuki SO, Nakabeppu Y, Iwaki T . Impairment of mitochondrial DNA repair enzymes against accumulation of 8-oxo-guanine in the spinal motor neurons of amyotrophic lateral sclerosis . Acta Neuropathologica . 103 . 4 . 408–414 . April 2002 . 11904761 . 10.1007/s00401-001-0480-x . 2102463 .
  20. Warita H, Hayashi T, Murakami T, Manabe Y, Abe K . Oxidative damage to mitochondrial DNA in spinal motoneurons of transgenic ALS mice . Brain Research. Molecular Brain Research . 89 . 1–2 . 147–152 . April 2001 . 11311985 . 10.1016/S0169-328X(01)00029-8 .
  21. Rosen DR, Bowling AC, Patterson D, Usdin TB, Sapp P, Mezey E, McKenna-Yasek D, O'Regan J, Rahmani Z, Ferrante RJ . 6 . A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis . Human Molecular Genetics . 3 . 6 . 981–987 . June 1994 . 7951249 . 10.1093/hmg/3.6.981 .
  22. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, Brown RH . 6 . Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis . Annals of Neurology . 41 . 2 . 210–221 . February 1997 . 9029070 . 10.1002/ana.410410212 . 25595595 . free .
  23. Valentine JS, Hart PJ . Misfolded CuZnSOD and amyotrophic lateral sclerosis . Proceedings of the National Academy of Sciences of the United States of America . 100 . 7 . 3617–3622 . April 2003 . 12655070 . 152971 . 10.1073/pnas.0730423100 . free . 2003PNAS..100.3617V .
  24. Broom WJ, Johnson DV, Auwarter KE, Iafrate AJ, Russ C, Al-Chalabi A, Sapp PC, McKenna-Yasek D, Andersen PM, Brown RH . 6 . SOD1A4V-mediated ALS: absence of a closely linked modifier gene and origination in Asia . Neuroscience Letters . 430 . 3 . 241–245 . January 2008 . 18055113 . 10.1016/j.neulet.2007.11.004 . 46282375 .
  25. Muller FL, Liu Y, Jernigan A, Borchelt D, Richardson A, Van Remmen H . MnSOD deficiency has a differential effect on disease progression in two different ALS mutant mouse models . Muscle & Nerve . 38 . 3 . 1173–1183 . September 2008 . 18720509 . 10.1002/mus.21049 . 23971601 .
  26. Bergemalm D, Jonsson PA, Graffmo KS, Andersen PM, Brännström T, Rehnmark A, Marklund SL . Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models . The Journal of Neuroscience . 26 . 16 . 4147–4154 . April 2006 . 16624935 . 6673995 . 10.1523/JNEUROSCI.5461-05.2006 .
  27. Pan L, Yoshii Y, Otomo A, Ogawa H, Iwasaki Y, Shang HF, Hadano S . Different human copper-zinc superoxide dismutase mutants, SOD1G93A and SOD1H46R, exert distinct harmful effects on gross phenotype in mice . PLOS ONE . 7 . 3 . e33409 . 2012 . 22438926 . 3306410 . 10.1371/journal.pone.0033409 . free . 2012PLoSO...733409P .
  28. Bhattacharya A, Bokov A, Muller FL, Jernigan AL, Maslin K, Diaz V, Richardson A, Van Remmen H . 6 . Dietary restriction but not rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS . Neurobiology of Aging . 33 . 8 . 1829–1832 . August 2012 . 21763036 . 10.1016/j.neurobiolaging.2011.06.002 . 11227242 .
  29. Vargas MR, Johnson DA, Johnson JA . Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mice model . Neurobiology of Disease . 43 . 3 . 543–551 . September 2011 . 21600285 . 3139005 . 10.1016/j.nbd.2011.04.025 .
  30. Komatsu T, Duckyoung Y, Ito A, Kurosawa K, Maehata Y, Kubodera T, Ikeda M, Lee MC . 6 . Increased oxidative stress biomarkers in the saliva of Down syndrome patients . Archives of Oral Biology . 58 . 9 . 1246–1250 . September 2013 . 23714170 . 10.1016/j.archoralbio.2013.03.017 .
  31. Pallardó FV, Degan P, d'Ischia M, Kelly FJ, Zatterale A, Calzone R, Castello G, Fernandez-Delgado R, Dunster C, Lloret A, Manini P, Pisanti MA, Vuttariello E, Pagano G . 6 . Multiple evidence for an early age pro-oxidant state in Down Syndrome patients . Biogerontology . 7 . 4 . 211–220 . August 2006 . 16612664 . 10.1007/s10522-006-9002-5 . 13657691 .
  32. Casareno RL, Waggoner D, Gitlin JD . The copper chaperone CCS directly interacts with copper/zinc superoxide dismutase . The Journal of Biological Chemistry . 273 . 37 . 23625–23628 . September 1998 . 9726962 . 10.1074/jbc.273.37.23625 . free .
  33. Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, Brown RH . Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria . Neuron . 43 . 1 . 19–30 . July 2004 . 15233914 . 10.1016/j.neuron.2004.06.021 . 18141051 . free .
  34. Cova E, Ghiroldi A, Guareschi S, Mazzini G, Gagliardi S, Davin A, Bianchi M, Ceroni M, Cereda C . 6 . G93A SOD1 alters cell cycle in a cellular model of Amyotrophic Lateral Sclerosis . Cellular Signalling . 22 . 10 . 1477–1484 . October 2010 . 20561900 . 10.1016/j.cellsig.2010.05.016 .
  35. Cereda C, Cova E, Di Poto C, Galli A, Mazzini G, Corato M, Ceroni M . Effect of nitric oxide on lymphocytes from sporadic amyotrophic lateral sclerosis patients: toxic or protective role? . Neurological Sciences . 27 . 5 . 312–316 . November 2006 . 17122939 . 10.1007/s10072-006-0702-z . 25059353 .
  36. Cova E, Cereda C, Galli A, Curti D, Finotti C, Di Poto C, Corato M, Mazzini G, Ceroni M . 6 . Modified expression of Bcl-2 and SOD1 proteins in lymphocytes from sporadic ALS patients . Neuroscience Letters . 399 . 3 . 186–190 . May 2006 . 16495003 . 10.1016/j.neulet.2006.01.057 . 26076370 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "SOD1".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.